Objective: To present the results of a systematic review of literature published between 1980 and 2004 reporting findings of the prevalence and incidence of anxiety disorders in the general population.
I n recent years, it has been increasingly acknowledged not only that anxiety disorders are highly prevalent, but also that the burden of illness associated with these disorders is often considerable. A broad understanding of the etiology of anxiety includes a multiplicity of factors, such as biological, psychological, and social determinants, which are mediated by a range of risk and protective factors. Cross-cultural studies in epidemiology are a critical source of information regarding the interplay between these factors. Effective forms of intervention are available and are the subject of ongoing research, but it is an immense public health challenge to coordinate the delivery of these programs and services. Studies in comparative epidemiology play a vital role in the development of health policy concerning anxiety. Empirical knowledge of regional prevalence is fundamental to understanding the relative demand for services. Such knowledge is also necessary to identify the most appropriate avenues for intervention.
The present review, which is the fifth in a series of papers that will present systematic reviews of the prevalence and incidence of psychiatric disorders drawn from studies published in the English literature in the years 1980 to 2004, sought to synthesize international research on this topic. Results and observed patterns of heterogeneity are discussed in relation to health services planning as well as implications for additional research.
Methods
The methods employed in this review have been presented in more detail elsewhere (1) . The MEDLINE and HealthSTAR databases were searched for relevant studies; the key indexing terms epidemiology, prevalence, and incidence were used, combined with the search terms mental disorders, anxiety disorders, panic disorder, phobia, obsessive-compulsive disorder, posttraumatic stress disorder, and generalized anxiety disorder. The search was limited to English-language studies published between 1980 and 2004. Reference lists of relevant primary and review articles identified were also searched.
Prevalence and incidence studies were eligible for inclusion if they were community surveys using probability sampling techniques. Eligible publications were restricted to studies having sample sizes of 450 people or more that examined age ranges covering the adult population. Only studies using current diagnostic criteria and case identification based on either standardized instruments or clinician diagnosis were included. Prevalence and incidence data, including overall, sex-specific and age-specific rates, were extracted from eligible studies.
Qualitative analyses of variables related to methodology were conducted to summarize and elucidate any observed differences between rates. Each set of rates was also pooled according to a Bayesian approach to metaanalysis; the Fastpro software program was used. Readers interested in a more detailed discussion of this approach should refer to Eddy and others (2) . Each of the pooled rates was analyzed for heterogeneity with chi-square tests according to the Fleiss method (3).
Results

Description of Studies
From the citations and abstracts generated by the initial electronic search, we identified 80 prevalence and 10 incidence studies potentially meeting inclusion criteria, in addition to 28 review papers . The full texts of these articles were retrieved. We searched all reference lists of identified studies and reviews, generating an additional 38 prevalence and 6 incidence studies for which full-text articles were obtained.
Of the 118 prevalence studies for which full-text articles were reviewed, 71 prevalence papers of anxiety disorders met eligibility criteria (96) (97) (98) (99) (100) (101) (102) , resulting in a total of 41 unique primary investigations of anxiety disorders included in this review. We excluded a total of 47 studies: 35 studies did not meet eligibility criteria, and 12 presented duplicate data. Of the 16 incidence studies identified, 11 were excluded, 8 did not meet inclusion criteria, and 3 were based on duplicate study samples. This resulted in 5 incidence studies of anxiety disorders that could be included (54, 90, (103) (104) (105) . Most studies meeting inclusion criteria used nonhierarchical diagnostic approaches. Predictably, the few studies using hierarchical diagnoses reported relatively lower rates of individual disorders. 
Qualitative Analysis
Total Anxiety Disorders
For TADs, 1-year prevalence rates ranged from 4.2% in Florence, Italy (95) , to 17.2% in the NCS (39), which is a variation of 4.1-fold ( Table 1) . The study with the lowest rate, conducted in Florence, Italy, employed the SADS-L to identify cases, whereas most other studies used the CIDI. Lifetime prevalence rates ranged from 9.2% in Korea (40) to 28.7% in Basle, Switzerland (48), a variation of slightly over 3-fold. The study conducted in Basle, Switzerland, was the only one to use clinical interviewers, while all other studies employed lay interviewers and diagnostic algorithms. Further, studies with the lowest rates used the DIS and DSM-III criteria, whereas other studies used the CIDI and DSM-III-R criteria. Tables 2 and 3 present findings from studies reporting sex-specific 1-year and lifetime prevalence rates, respectively, for anxiety disorders. For TADs, 1-year and lifetime prevalence rates were generally found to be about twice as high for women, compared with men. Studies reporting 1-year and lifetime sex-specific rates for panic disorder showed consistently higher rates for women, compared with men, but varied in the magnitude of this difference with rates that were 1.2-fold (34) to 6.8-fold (40) higher for women than men. Most rates for panic disorder, however, were generally found to be between 2 and 3.5 times higher for women, compared with men. With regard to phobic disorders, 1-year and lifetime prevalence rates were generally found to be between 2 and 4 times higher for women, compared with men, for agoraphobia and specific phobia. While most 1-year and lifetime rates for social phobia were found to be between 1.2 and 2.6 times higher for women, compared with men, there were studies reporting lifetime rates for women that were 5 times (38) and 12.5 times (40) rates for men. Furthermore, there were studies demonstrating higher lifetime prevalence rates for social phobia in men, compared with women (38, 43) .
Sex-Specific Prevalence
For OCD, there was little consistency observed for sex-specific rates. Most rates were found to be higher for women than for men but several studies demonstrated higher rates for men, compared with women (32, 34, 38) . For studies reporting higher female rates, most rates were 1.1 to 1.8 times higher for women than for men, while one study found a female rate that was 14.8 times that of the male rate (77) . With regard to GAD, the 1-year and lifetime rates were generally found to be 1.5 to 2 times higher for women, compared with men. Figure 1 presents results from each study reporting age-specific lifetime prevalence rates for anxiety disorders.
Age-Specific Lifetime Prevalence
As shown, lifetime prevalence rates for agoraphobia and OCD appear to remain fairly stable throughout ages 18 to 64 years. For social phobia, there seems to be a slight decrease in prevalence with increasing age. When all anxiety disorders are taken together, there appears to be an increase in lifetime prevalence throughout ages 18 to 64 years.
Qualitative observations associated with individual anxiety disorders appear alongside the results presented in the following section.
Estimation and Heterogeneity Analysis of Pooled Best-Estimate Rates
Total Anxiety Disorders
The best-estimate rates for 1-year and lifetime prevalence of TADs were 10.6% (95%CI, 7.5% to 14.3%) and 16.6% (95%CI, 12.7% to 21.1%), respectively ( Table 1 ). The CI variations for the 1-year and lifetime prevalence estimates are 1.9-fold and 1.7-fold, respectively, which are lower than the respective 4.1-fold and 3.1-fold variations observed across individual rates. Heterogeneity analysis of 1-year and lifetime prevalence rates revealed significant differences across each set of proportions. Chi-square tests for heterogeneity were conducted for the following variables: country studied, year study published, type of sample (that is, national, regional, or municipal); sample size; sample inclusion (that is, community only or community and institutional), diagnostic instrument used, type of interviewer (that is, lay or clinician), mode of establishing diagnosis (that is, algorithm or clinical judgment), and diagnostic criteria used. Variables that may be contribute to heterogeneity are shown in Table 4 . For lifetime prevalence, the diagnostic criteria and instruments used were variables that may have contributed to heterogeneity ( Table  4 ). Studies that employed the DIS and DSM-III criteria had pooled lifetime rates that were almost 2 times lower than those of studies that used other diagnostic instruments and criteria. 
Panic Disorder
The best-estimate rates for 1-year and lifetime prevalence were 0.99% (95%CI, 0.55% to 1.5%) and 1.2% (95%CI, 0.7% to 1.9%), respectively ( Table 1 ). The variations in the 1-year and lifetime prevalence rates, as shown by the CIs, are both 2.7-fold. Across individual studies, the 1-year prevalence rates ranged from 0.13% in rural villages in Taiwan (38) to 3.2% in Florence, Italy (95), which is a difference of almost 25-fold. Lifetime prevalence rates for panic disorder ranged from 0.13% in rural villages in Taiwan (38) to 3.8% in the Netherlands (32), a variation of approximately 29-fold. Heterogeneity analysis demonstrated significant differences across 1-year and lifetime prevalence rates of panic disorder. For studies conducted in Asia, the pooled 1-year rates were found to be approximately 9 times lower than that of studies conducted elsewhere (Table 4 ). All studies with lifetime prevalence rates under 3.0% used DSM-III criteria and, for the most part, the DIS, whereas all studies with rates above 3.0% employed the CIDI and DSM-III-R criteria.
Agoraphobia
The best-estimate rates for 1-year and lifetime prevalence were 1.6% (95%CI, 1.0% to 2.3%) and 3.8% (95%CI, 2.5% to 5.6%), respectively ( Non-Asian 
Social Phobia
The best-estimate rates for 1-year and lifetime prevalence were 4.5% (95%CI, 3.0% to 6.4%) and 3.6% (95%CI, 2.0% to 5.6%), respectively (Table 1) . Across individual studies, 1-year prevalence rates ranged from 2.3% in France (62) (50) . This is a difference of 86-fold. Excluding the outlying rate reported in Udmurtia, the rates vary up to 16.0%, which is a variation of approximately 30-fold. The CI variations for the 1-year and lifetime best-estimate rates are 2.1-fold and 2.8-fold, respectively, which are much lower than the respective 3.4-fold and 30-fold differences observed across individual rates. Inclusion of the outlying rate in the pooled estimate would produce a 1-year and lifetime prevalence of 6.3% (95%CI, 2.9% to 10.8%) and 4.5% (95%CI, 2.3% to 7.2%), respectively. Significant differences were found among 1-year and lifetime prevalence rates of social phobia. For studies using the DIS, the pooled lifetime prevalence was 4 times lower than that of studies using other diagnostic instruments (Table  4) . Similarly, for studies using DSM-III criteria, the pooled lifetime prevalence was over 5 times lower than that of studies using other diagnostic criteria. In general, studies reporting lifetime rates under 4.0% employed the DIS and DSM-III criteria, while studies reporting rates above 4.0% used the CIDI and DSM-III-R criteria.
Specific Phobia
The best-estimate rates for 1-year and lifetime prevalence were 3.0% (95%CI, 0.98% to 5.8%) and 5.3% (95%CI, 3.4% to 7.9%), respectively ( Table 1 ). The variations in the CI for these 1-year and lifetime prevalence rates are almost 6-fold and 2.3-fold respectively. By contrast, prevalence rates reported across (88), to 11.3% in the US (NCS) (39) , which is a difference of almost 18-fold. Heterogeneity was demonstrated for 1-year and lifetime prevalence rates of specific phobia. For studies conducted in North America, the pooled 1-year rate was almost 4 times higher, compared with that of studies outside North American countries (Table 4) . For both 1-year and lifetime rates, the study conducted in Italy, which reported the lowest rates, employed the SADS-L, whereas the remaining studies used the CIDI or DIS.
Obsessive-Compulsive Disorder
The best-estimate rates for 1-year and lifetime prevalence were 0.54% (95%CI, 0.28% to 0.86%) and 1.3% (95%CI, 0.86% to 1.8%), respectively ( Table 1 ). The variations in the CIs for these 1-year and lifetime prevalence rates are approximately 3-fold and 2-fold respectively. Across individual studies, variations of 13.8-fold and 10.7-fold respectively, were observed. Heterogeneity was demonstrated for 1-year and lifetime prevalence rates of OCD. For studies conducted in Asian countries or with response rates of 80% or lower, the pooled 1-year rates were approximately 4 times lower, compared with those of studies conducted outside Asian countries or with response rates of more than 80% (Table 4) . For pooled lifetime rates, studies conducted in Asian countries produced rates that were almost 2 times lower than studies conducted outside Asia. Examination of each of the studies does not reveal any relevant methodological differences that might help to explain the variation in rates of OCD.
Posttraumatic Stress Disorder
The best-estimate rates for 1-year and lifetime prevalence were 1.2% (95%CI, 0.09% to 3.4%) and 2.1% (95%CI, 0.4% to 4.9%), respectively ( Table 1 ). The variation in the CIs for the 1-year pooled rate was approximately 37-fold, which is higher than the 33-fold difference found across individual rates. For lifetime prevalence, the variation in the CIs was approximately 12-fold, which is considerably lower than the 62-fold variation observed across individual rates. Heterogeneity was demonstrated for lifetime prevalence rates of PTSD. Further analysis to determine which variables may be contributing to heterogeneity was not carried out, owing to the small number of rates. The lowest rate reported was based on the SADS-L and clinical interviews and diagnoses, while all other studies were based on the DIS or CIDI and lay interviewers.
Generalized Anxiety Disorder
The best-estimate rates for 1-year and lifetime prevalence were 2.6% (95%CI, 1.4% to 4.2%) and 6.2% (95%CI, 4.0% to 9.2%), respectively ( (55) . Heterogeneity was demonstrated for 1-year and lifetime prevalence rates of GAD. Studies employing DIS-DSM-III or published before 1994 produced a pooled 1-year rate that was 4.5 times higher than that of studies using other diagnostic instruments and criteria and published on or after 1994 (Table 4) . For studies conducted in European countries, the pooled lifetime rate was approximately 3 times lower, compared with that of studies conducted outside European countries. There were no apparent methodological differences to account for the variation in lifetime prevalence rates.
Incidence Studies
Five studies provided data on 1-year incidence rates of anxiety disorders. The incidence studies conducted in Edmonton, Canada (104) and the US (90, 103, 105) were prospective follow-up studies of community-based samples with total populations ranging from 1964 to 12 823. The study conducted in Norway (54) was also based on a community sample but involved a retrospective assessment of incidence. The prospective studies used the DIS and an algorithm to extract diagnoses, whereas the retrospective study employed the CIDI and a clinician diagnosis. An inadequate number of rates from unique primary investigations were available for the various anxiety disorder categories; therefore, the rates are presented for the sake of interest, and no analyses of the rates were performed.
Discussion
The results of this study further confirm the high international prevalence of anxiety disorders, and illustrate patterns of considerable heterogeneity. Best-estimates for the 1-year and lifetime prevalence of TADs were 10.6% and 16.6%, respectively. The ratio between 1-year and lifetime rates indicates that a large number of people experience anxiety disorders on a continuing or recurring basis.
Across studies, anxiety disorders were approximately twice as prevalent among women, with overall age-specific rates remaining relatively stable or increasing across the lifespan. Overall, the results suggest a burden of illness that eclipses the capacity of specialized mental health service providers.
Between studies, there was considerable variability on all observed prevalence rates. For most categories of anxiety disorder there was at least a 10-fold variation between the prevalence rates reported by different studies. In contrast, the degree of variability between rates of TADs was much smaller than the variation associated with individual disorders.
Perhaps a predisposition to one of several anxiety disorders could be differentially expressed in other contexts. Similarly, specific anxiety symptoms may vary over the course of time, crossing diagnostic boundaries but without relief from suffering. Alternatively, there may be cross-cultural differences in the genetic basis of one or more of the anxiety disorders. The pattern of results is consistent with the view that anxiety disorders are determined by a multiplicity of factors, including biological, psychological, and social variables.
A few methodological factors were associated with the observed heterogeneity between rates. Pooled rates for TADs were lower in studies that incorporated DIS and DSM-III criteria than in studies using the CIDI and DSM-III-R. This pattern was also observed for some studies that estimate the prevalence of individual disorders. Several other factors were associated with heterogeneity, including the country studied, the response rate, and the size of the study sample. However, each of these factors was available for evaluation in relation to a small number of individual disorders. In most cases, different studies were distinguished on the basis of several factors simultaneously (for example, location, type of disorders investigated, method of diagnosis, and sample size). Hence, it is not possible to attribute unique variance to any one of these potential sources of variability. Three studies used different diagnostic schemes with the same subjects. However, there was no consistent pattern to the results associated with different criteria across this small number of studies.
An insufficient number of incidence studies were available for inclusion, signalling an important omission in the epidemiologic literature. Further knowledge is required about the onset of anxiety disorders, including risk and protective factors, as well as social variables that may mediate the expression of these disorders and help explain the level of heterogeneity observed in the present study.
There is a dearth of information regarding the prevalence of anxiety disorders among special populations. Some research suggests that risk of anxiety may be greater within certain subgroups, such as medical patients (109) and residents of nursing homes (110) . Further investigation of these and other subgroups is required to identify concentrations of need and hasten the deployment of requisite services.
As a class, anxiety disorders are seldom treated. Only a limited subset of treatment appears to be consistent with evidence-based recommendations (79) . The challenge of reducing the burden of illness associated with anxiety disorders is immense. To meet this challenge, it is essential to further clarify the epidemiology of anxiety, which will allow for the targeted deployment of programs and services on the basis of a probabilistic understanding of need. 
Conclusion :
La prévalence internationale des troubles anxieux varie grandement entre les rapports épidémiologiques publiés. La variabilité associée à tous les troubles anxieux est considérablement plus modeste que la variabilité associée aux troubles individuels. Les femmes déclarent des taux plus élevés de troubles anxieux que les hommes. Plusieurs facteurs se sont révélés associés à l'hétérogénéité parmi les taux, dont les critères diagnostiques, l'instrument diagnostique, la taille de l'échantillon, le pays étudié et le taux de réponse.
